Concepts (96)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 9 | 2025 | 1192 | 1.340 |
Why?
|
| Graft vs Host Disease | 4 | 2023 | 621 | 0.940 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2019 | 19 | 0.600 |
Why?
|
| Periosteum | 1 | 2019 | 33 | 0.580 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2023 | 571 | 0.510 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 351 | 0.480 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 445 | 0.430 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2025 | 146 | 0.400 |
Why?
|
| Organ Transplantation | 2 | 2025 | 181 | 0.390 |
Why?
|
| CRISPR-Cas Systems | 2 | 2025 | 293 | 0.360 |
Why?
|
| Graft Rejection | 2 | 2025 | 560 | 0.350 |
Why?
|
| Transplantation Conditioning | 4 | 2023 | 300 | 0.250 |
Why?
|
| Streptococcus pyogenes | 1 | 2025 | 79 | 0.220 |
Why?
|
| Nucleic Acid Conformation | 1 | 2024 | 182 | 0.220 |
Why?
|
| CRISPR-Associated Proteins | 1 | 2024 | 6 | 0.220 |
Why?
|
| beta-Thalassemia | 1 | 2023 | 30 | 0.210 |
Why?
|
| Endodeoxyribonucleases | 1 | 2024 | 47 | 0.210 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2023 | 47 | 0.200 |
Why?
|
| Antibodies, Bispecific | 1 | 2023 | 52 | 0.200 |
Why?
|
| Gene Editing | 1 | 2025 | 212 | 0.190 |
Why?
|
| Burkitt Lymphoma | 1 | 2023 | 141 | 0.190 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2025 | 499 | 0.180 |
Why?
|
| Lung Diseases | 1 | 2025 | 409 | 0.180 |
Why?
|
| Databases, Genetic | 1 | 2024 | 500 | 0.180 |
Why?
|
| RNA | 1 | 2024 | 549 | 0.170 |
Why?
|
| Hematologic Diseases | 1 | 2021 | 82 | 0.160 |
Why?
|
| RNA, Viral | 1 | 2022 | 566 | 0.160 |
Why?
|
| Bacterial Proteins | 1 | 2025 | 929 | 0.160 |
Why?
|
| DNA | 1 | 2025 | 1484 | 0.160 |
Why?
|
| Child | 10 | 2025 | 25823 | 0.150 |
Why?
|
| Escherichia coli | 1 | 2024 | 995 | 0.150 |
Why?
|
| Hodgkin Disease | 1 | 2022 | 305 | 0.150 |
Why?
|
| Acute Disease | 1 | 2022 | 1176 | 0.150 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2025 | 898 | 0.150 |
Why?
|
| Anemia, Sickle Cell | 1 | 2021 | 344 | 0.130 |
Why?
|
| Lower Extremity | 1 | 2019 | 188 | 0.130 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 816 | 0.130 |
Why?
|
| Humans | 16 | 2025 | 132334 | 0.120 |
Why?
|
| Child, Preschool | 5 | 2025 | 14851 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 402 | 0.110 |
Why?
|
| T-Lymphocytes | 1 | 2023 | 1759 | 0.110 |
Why?
|
| Young Adult | 5 | 2025 | 9945 | 0.100 |
Why?
|
| Retrospective Studies | 7 | 2025 | 17363 | 0.100 |
Why?
|
| Graft Survival | 2 | 2025 | 475 | 0.100 |
Why?
|
| Alemtuzumab | 2 | 2023 | 88 | 0.100 |
Why?
|
| Tissue and Organ Procurement | 2 | 2025 | 247 | 0.090 |
Why?
|
| Adolescent | 6 | 2025 | 20552 | 0.090 |
Why?
|
| Neuroblastoma | 1 | 2017 | 550 | 0.090 |
Why?
|
| Immunotherapy | 1 | 2017 | 748 | 0.090 |
Why?
|
| Mutation | 1 | 2024 | 6248 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2025 | 3710 | 0.080 |
Why?
|
| Treatment Outcome | 4 | 2025 | 13016 | 0.070 |
Why?
|
| Adult | 5 | 2025 | 31618 | 0.070 |
Why?
|
| Survival Rate | 2 | 2025 | 2187 | 0.060 |
Why?
|
| Neoplasms | 1 | 2021 | 2944 | 0.060 |
Why?
|
| Female | 5 | 2025 | 70786 | 0.060 |
Why?
|
| Nucleotide Motifs | 1 | 2025 | 48 | 0.060 |
Why?
|
| Aged | 4 | 2025 | 21379 | 0.060 |
Why?
|
| Time Factors | 2 | 2025 | 6455 | 0.060 |
Why?
|
| Respiratory Function Tests | 1 | 2025 | 213 | 0.060 |
Why?
|
| RNA, Ribosomal | 1 | 2024 | 57 | 0.060 |
Why?
|
| Infant | 3 | 2025 | 13192 | 0.050 |
Why?
|
| Encyclopedias as Topic | 1 | 2024 | 6 | 0.050 |
Why?
|
| Ribosomes | 1 | 2024 | 125 | 0.050 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2023 | 11 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2025 | 6540 | 0.050 |
Why?
|
| Busulfan | 1 | 2023 | 43 | 0.050 |
Why?
|
| CD40 Antigens | 1 | 2023 | 27 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 1303 | 0.050 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2023 | 150 | 0.050 |
Why?
|
| Texas | 2 | 2021 | 3628 | 0.050 |
Why?
|
| HEK293 Cells | 1 | 2025 | 796 | 0.050 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2023 | 100 | 0.050 |
Why?
|
| Carmustine | 1 | 2022 | 25 | 0.050 |
Why?
|
| Melphalan | 1 | 2022 | 46 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2023 | 648 | 0.050 |
Why?
|
| Cytarabine | 1 | 2022 | 102 | 0.050 |
Why?
|
| Male | 5 | 2025 | 65052 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2022 | 287 | 0.040 |
Why?
|
| Unrelated Donors | 1 | 2021 | 70 | 0.040 |
Why?
|
| Phylogeny | 1 | 2024 | 767 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 425 | 0.040 |
Why?
|
| Rituximab | 1 | 2022 | 166 | 0.040 |
Why?
|
| Risk Factors | 2 | 2025 | 10910 | 0.040 |
Why?
|
| Recurrence | 1 | 2023 | 1458 | 0.040 |
Why?
|
| Middle Aged | 3 | 2025 | 28888 | 0.040 |
Why?
|
| Prevalence | 1 | 2025 | 2664 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 436 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2025 | 5405 | 0.030 |
Why?
|
| Prognosis | 1 | 2025 | 5009 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2023 | 3697 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 1347 | 0.030 |
Why?
|
| Pandemics | 1 | 2021 | 1188 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1297 | 0.030 |
Why?
|
| Mice | 1 | 2023 | 18571 | 0.010 |
Why?
|
| Animals | 1 | 2023 | 34989 | 0.010 |
Why?
|